Company Overview of Sumagen Co., Ltd.
Sumagen Co., Ltd., a biotechnology company, engages in developing human immunodeficiency virus/acquired immune deficiency syndrome vaccine and a vaccine to treat hepatitis C virus. The company was founded in 2000 and is based in Seoul, South Korea with a location in London, Canada. Sumagen Co., Ltd. operates as a subsidiary of CUROCOM.Co.Ltd.
Dongwon B/D 4F
Founded in 2000
82 2 2141 2800
82 2 2141 2810
Key Executives for Sumagen Co., Ltd.
Similar Private Companies By Industry
|Advanced Protein Technologies Corporation||Asia|
|Aetna Genetech Inc.||Asia|
Recent Private Companies Transactions
September 7, 2016
August 4, 2016
May 16, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Sumagen Co., Ltd., please visit www.sumagen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.